RESEARCH ARTICLE

Pharmacokinetics of Lidocaine Hydrochloride Administered with or without Adrenaline for the Paravertebral Brachial Plexus Block in Dogs

Amélie Choquette1*, Eric Troncy1, Martin Guillot1, France Varin2, Jérôme R. E. del Castillo1*☯

1 Québec’s Animal Pharmacology Research Group (GREPAQ), Department of Veterinary Biomedical Sciences, Université de Montréal, Saint-Hyacinthe, Québec, Canada, 2 Faculty of Pharmacy, Université de Montréal, Montréal, Québec, Canada

☯ These authors contributed equally to this work.
* jerome.del.castillo@umontreal.ca

Abstract

Adrenaline is known to prolong the duration of local anesthesia but its effects on the pharmacokinetic processes of local anesthetic drugs are not fully understood. Our objective was to develop a compartmental model for quantification of adrenaline’s impact on the pharmacokinetics of perineurally-injected lidocaine in the dog. Dogs were subjected to paravertebral brachial plexus block using lidocaine alone or adrenaline-injected lidocaine. Data was collected through a prospective, randomised, blinded crossover protocol performed over three periods. Blood samples were collected during 180 minutes following block execution. Compartmental pharmacokinetic models were developed and their goodness-of-fit were compared. The lowering effects of adrenaline on the absorption of lidocaine were statistically determined with one-sided tests. A one-compartment disposition model with two successive zero-order absorption processes best fitted our experimental data. Adrenaline decreased the peak plasma lidocaine concentration by approximately 60% ($P < 0.001$), decreased this local anesthetic’s fast and slow zero-order absorption rates respectively by 50% and 90% ($P = 0.046$, and $P < 0.001$), which respective durations were prolonged by 90% and 1300% ($P < 0.020$ and $P < 0.001$). Lidocaine demonstrated a previously unreported atypical absorption profile following its paravertebral injection in dogs. Adrenaline decreased the absorption rate of lidocaine and prolonged the duration of its absorption.

Introduction

The concept of multimodal and pre-emptive analgesia has popularized the use of local and regional anesthetic blocks in small animal veterinary practice [1] Newly implemented dosage regimens, drug combinations and block techniques improve pain management for a variety of medical or surgical conditions [2–4]. Yet, the range of desensitization techniques is much
supporting salaries) from the Natural Sciences and Engineering Research Council of Canada, as well as by an ongoing New Opportunities Fund grant (#9483) and a Leader Opportunity Fund grant (#24601), supporting pain/function equipment, from the Canada Foundation for Innovation. M. Guillot was the recipient of a Scholarship for postdoctoral research from Natural Sciences and Engineering Research Council of Canada (NSERC). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: Eric Troncy has been regular consultant for Abbott Animal Health, and occasional consultant for Akron Molecules AG, Axience Santé Animale, Boehringer Ingelheim Vetmedica Inc., Centrexion Inc., CEVA Santé Animale, Disponed Ltee, Elanco Animal Health, Ferring Pharmaceuticals Inc., MSD Animal Health Innovation SAS, Novartis Animal Health Inc., Vetoquinol, and Zoetis. None of these corporations involved in the current project. All other authors have no conflicts of interest to declare. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

narrower for the canine forelimb than for the hindlimb. The subscapular approach to the brachial plexus block is efficacious at desensitizing the forelimb from elbow to toes, but its effect proximal to the elbow is unpredictable at best [5,6] By targeting the nerve roots as they exit the vertebral foramen, the original and the modified paravertebral blocks of the brachial plexus seem promising for anesthetising the shoulder and brachium [7], but both approaches give inconsistent results and warrant further investigation.

Lidocaine is used in a variety of local anesthetic procedures, both in human and veterinary medicine, and its pharmacokinetics has been studied in different species for over 40 years [8,9]. Its destiny after intravenous and extravascular administration has been studied with different formulations, dosages or anesthetic contexts [10–12]. Yet, we are unaware of a published study describing the pharmacokinetics of lidocaine following peripheral nerve block in dogs.

Furthermore, several local anesthetics are available in solutions containing adrenaline, which decreases the regional blood flow and the rate of lidocaine absorption at injection site, hence extending the duration of the exposure of the targeted nerves to effective anesthetic concentrations [13]. Still, the effects of adrenaline on the absorption of lidocaine have not been thoroughly characterized [14], at least for this particular technique.

Among the few publications describing the effect of adrenaline on the pharmacokinetics of extravascular-administered local anesthetics, one used an interesting model to quantify the effect of adrenaline on the absorption of levobupivacaine following caudal epidural administration in children: these investigators fitted the drug’s time-concentration data to a model with two distinct first-order absorption rate constants whose onsets were separated by a lag time [15]. We hypothesized that this model could (1) be applied to other amide-type local anesthetics and extravascular administration sites, including the brachial plexus, and (2) accurately measure the lowering effects of adrenaline on the absorption rate of lidocaine. To verify our hypotheses, we performed a pharmacokinetic study of lidocaine either alone or combined with adrenaline. Our objectives were: first, to compare the goodness-of-fit of the above-described dual-absorption compartmental model (alternative model) and of the basic one-compartment model with a single first-order absorption process (standard model) to the plasma lidocaine data of both drug formulations (i.e. plain and adrenalinedated lidocaine). Second, to determine whether the model with the highest goodness-of-fit could be further improved, and third, to quantify the effect of adrenaline on the absorption pharmacokinetics of lidocaine by analyzing the time-concentration data of both drug formulations with the best model.

Materials & Methods

The study protocol was reviewed and approved by the Faculté de Médecine Vétérinaire Bioethics Committee (CEUA) of the Université de Montréal (protocol #Rech-1574). Animals were housed and handled following the guidelines of the Canadian Council on Animal Care. At the end of the study, the animals were returned alive and healthy to the institutional animal colony.

Animals

Eight healthy female beagles, 2 to 5 years old, and weighing 11 (1.3) [mean (SD)] kg were used. They belong to our institutional Teaching & Research dog colony, where they are housed together in facilities that are approved by the Canadian Council on Animal Care, and accustomed to human interaction and manipulation by the veterinary students of the Comité d’Éthique et Bien-Être des Animaux (CEBA). The students interacted with them and exercised them daily except on the days of experimentation. Initial health status was assessed with a physical examination and standard blood tests (hematocrit, total proteins, uremia). Prior to each anesthesia, dogs were re-examined, weighed and fasted for 12 hours with free access to water.
Study design and procedures

Dogs were sedated with an intramuscular combination of 10 μg/kg medetomidine hydrochloride and 0.1 mg/kg butorphanol tartrate. A 30-mm 20-gauge cephalic intravenous catheter was placed in the right cephalic vein for drug administration and blood sampling. Anesthesia was then induced with propofol to effect (maximum dose of 4 mg/kg), followed by endotracheal intubation and maintenance with ≥2% isoflurane in oxygen, as targeted on the vaporizer. Once the anesthesia depth was stabilized according to clinical signs, dogs were positioned in right recumbency, with the left forelimb pulled far caudally to improve visualization of the cervical seventh (C7) transverse process and the head of the first rib. To minimize the variability in block execution, all injections were performed on the left forelimb by the same left-handed investigator (A.C.). The fur along the lateral aspect of the neck was clipped from the transverse processes of C4 to the mid-scapula and from the spinous processes to the jugular groove. The skin was disinfected with isopropanol, which was also used instead of gel to facilitate transducer-skin contact. Ultrasound imaging (M-Turbo Vet™; FUJIFILM SonoSite Inc., Bothell, WA), was performed with a 6–15 MHz linear probe (HFL 50X Linear Transducer; FUJIFILM SonoSite Inc., Bothell, WA), using color-flow Doppler.

The ultrasound approach of Bagshaw et al. [16] was used in order to position the insulated needle (Echostim facet tip, 21-gauge, 40 mm; Havel’s Inc., Cincinnati, OH, USA) as close as possible to the nerve roots of C6, C7, and the junction of C8 and T1. Great care was taken not to lacerate/puncture a vessel or the targeted nerve sheath. Once the needle in position, the electrical stimulation technique (Stimuplex® Dig RC, Braun Medical Inc., Bethlehem, PA, USA) was combined to ultrasound visualisation in order to validate needle positioning through the characteristic motor responses for each root: shoulder rotation with C6, elbow flexion with C7 and carpus/digits flexion with C8-T1 [7]. Details of the guided loco-regional block and rationale for diluting the tested local anesthetic solutions are subject of a separate publication [17].

Dogs were randomly assigned to one of two treatment groups using a block balanced randomized crossover design. The randomization was controlled for age, gender and body weight. Treatments consisted of commercially available injectable solutions containing 20 mg/mL of lidocaine hydrochloride, either alone or combined with 0.01 mg/mL adrenaline. Both formulations were diluted with sterile physiological saline at a 1:1 volume ratio prior to administration. For every block, 2 mg/kg lidocaine was administered per nerve root, to a total dose of 6 mg/kg per dog. After the third injection, isoflurane administration was immediately stopped and atipamezole hydrochloride administered intramuscularly at a dose of 50 μg/kg. Dogs were oxygenated until extubation and warmed as needed until they were awoken and capable of standing.

At the request of the bioethical committee, the dogs were used in three periods with a four-week washout between the first two treatments, and two weeks between second and third treatments. All washout periods exceed by at least 295 times the average 0.88 h terminal half-life of lidocaine in dogs [18]. In order to assure blindness of the investigators responsible for block execution and data collection, a technical assistant (D. G.) was in charge of randomization protocol and solution preparation.

Pharmacokinetics

**Blood sampling.** One mL of blood was drawn via the cephalic vein catheter before each blood sampling to remove its heparin lock. Then, 3 mL of blood were collected in heparin tubes at 5, 8, 12, 16, 20, 30, 45, 60, 80, 100, 130, and 180 minutes after the time of first injection of plain or adrenalinated lidocaine. A 3-mL blood sample was additionally drawn at approximately 2 minutes after each lidocaine injection to detect a possible variation in drug absorption...
rate across injection sites. The precise time of blood sampling was noted. The samples were kept on crushed ice for a maximum of 8 hours and then centrifuged at $1300 \times g$ and $4\,^\circ\text{C}$ for 10 minutes. Plasma was harvested and stored at $-80\,^\circ\text{C}$ pending analysis.

**Sample processing and analysis.** The plasma lidocaine concentrations were measured using an adaptation of a published liquid-liquid back-extraction procedure [19]. Briefly, 75 $\mu$L of internal standard bupivacaine 10 $\mu$g/mL solution (Sigma-Aldrich, Milwaukee, WI, USA) and 175 $\mu$L of sodium carbonate 10% were added to 0.5 mL of plasma. The extraction was completed by adding 3 mL of n-hexane:methylene (4:1, v:v) and agitating gently for 30 minutes. After centrifugation, organic layers were transferred and combined to 250 $\mu$L of sulfuric acid 50 mM for back extraction. The tubes were vortexed and centrifugated again, the organic phase was then aspirated to waste and residual solvent removed from the acid (SpeedVac™ Plus SC210A; Savant Instruments, Farmingdale, NY, USA). The residual volume was reconstituted in a mobile phase consisting in a 70:30 mixture of 70 mM sodium sulfate and acetonitrile, and injected into a HP1050 HPLC system (Hewlett Packard, Wilmington, DE, USA) fitted with a C$_8$ reversed-phase separation column (particle size 5$\mu$m, 150 mm x 4.6 mm inner diameter; Phenomenex, Torrance, CA, USA), and an UV detector set at 205 nm. Peak integration was performed using the Chem Station version A.09.01 (Agilent Technologies, Santa Clara, CA, USA). The mobile phase was prepared daily, injected at a 1.5 mL/min flow rate and maintained at $40\,^\circ\text{C}$. The analyte was spiked into a pool of drug-free plasma (4 mg/L) that was further diluted to yield standards at various concentrations down to the lowest limit of quantification (LLOQ) of 0.03125 mg/L.

The inter-assay precision and accuracy were 7% and 96.8%, respectively. The intra-assay accuracy was 97.1%, as assessed at two quality control concentrations (0.200 and 0.800 mg/L). The back-calculated concentrations were determined from the calibration curve of the day.

**Pharmacokinetic analysis.** The plasma concentration versus time data was subjected first to an exploratory non-compartmental analysis. The maximum plasma concentration ($C_{\text{max}}$) and time to maximum concentration ($t_{\text{max}}$) were determined directly from the data, and the total area under the curve (AUC) was calculated using the “linear-up / log-down” trapezoidal method. The terminal rate constant ($\lambda_z$), the AUC extrapolation to infinity, and the apparent total clearance (CL/F) and volume of distribution (V/F) were estimated using standard formulae. Then, the estimated CL/F and V/F were used as initial parameter values in the population PK analysis using the ADAPT 5 software (ADAPT 5; Biomedical Simulations Resource, USC, San Diego, CA, USA).

To achieve our first objective, two sets of differential equations were developed. The first set (Model A—“null hypothesis”) comprised a pair of one-compartment disposition systems, one per drug formulation coded with subscript $j$, with common CL/F and V/F and a single first-order absorption process ($k_{a,j}$) per system (Fig 1A). The second set (Model B—“alternative hypothesis”) was identical to Model A, except that each compartmental system had two first-order absorption processes ($k_{a1,j}$ and $k_{a2,j}$), of which $k_{a2,j}$ was regulated by a lag time ($\tau_j$). In addition, a partition parameter ($f_j$) estimated the dose fractions absorbed by each uptake process (Fig 1B).

To achieve our second objective, the residual analysis of Models A and B revealed that Model B could be refined into Model C (Fig 1C) by replacing the $k_{a1,j}$ and $k_{a2,j}$ of each compartmental system with two zero-order absorption processes ($k_{01,j}$ and $k_{02,j}$) that are active only for a specific duration (respectively, $\text{Dur}_{1,j}$ and $\text{Dur}_{2,j}$).

To fulfill our third objective, the data of both treatments (plain and adrenalinated lidocaine) was analyzed simultaneously and compared using all three pharmacokinetic models. The models were solved with maximum likelihood expectation-maximization methods (MLEM) using 3000 importance samples per iteration [20], assuming log-normally distributed
pharmacokinetic parameters, and a diagonal covariance matrix of estimable parameters. Model selection was based both on the value of the Akaike goodness of fit information criterion (AIC) [21], and by comparing the scattering of standardized regression residuals [20].

**Statistical analysis.** Statistical analysis was conducted using SAS® (SAS 9.3 Version; SAS Institute Inc., Cary, NC, USA). Descriptive statistics were used to assess group demographics, and values reported as percentages or mean (standard deviation, or SD). The estimated absorption kinetic parameters of the compartmental analysis, as well as the area under the plasma concentration curve between the time of dosing and the time of last measurable plasma concentration $AUC_{0-t_{last},j}$, $C_{max,j}$ and $t_{max,j}$ were compared at the $\alpha = 0.05$ significance level using one-sided Student’s $t$ tests on the raw or log-transformed values (e.g. for ln($k_{01,j}$), $H_0$: $\mu$ (adrenalinated lidocaine) $\geq \mu$ (plain lidocaine), and for ln($Dur_{1,j}$), $H_0$: $\mu$ (adrenalinated lidocaine) $\leq \mu$ (plain lidocaine), in compliance with the hypothesized lowering effects of adrenaline on the absorption rate of lidocaine).

### Results
The crossover study was completed within a 3-month span. Seven dogs were available for the first period, and eight dogs for the second: therefore, we performed a 3rd period with the missing dog plus three others (1 adrenalinated lidocaine, 2 plain lidocaine) that already completed the cross-over. In consequence, ten blocks were performed with plain lidocaine and nine with adrenalinated lidocaine.
The three injections were administered to each subject within four minutes. No significant cardio-pulmonary or hemodynamic effect, as indicated through respiratory rate, heart rate or blood pressure, was recorded during block execution. Two dogs developed a Horner’s syndrome that had no visible impact on their individual PK profiles, and resolved in 130 minutes following the reversal of anesthesia.

The individual time-courses of plasma lidocaine concentration following administration of the plain and adrenalinized lidocaine formulations are shown in Fig 2. The elimination phase following \( C_{\text{max}} \) was visibly steeper for plain lidocaine than for adrenalinized lidocaine. In addition, the inter-individual variability was greater for adrenalinized lidocaine during the first 50 minutes following drug administration. But beyond 135 min following drug administration, the plasma lidocaine concentrations and terminal slopes of both treatment groups were strikingly similar (Fig 2).

Model selection

Model A had a lower AIC value than model B (-2859.34 vs. -2524.94, respectively), but the scattering of its standardized regression residuals as a function of predicted plasma concentrations showed departure from the abscissa for both lidocaine formulations (Fig 3A and 3C), indicating respectively that this model underestimated the higher plasma lidocaine concentrations of the plain lidocaine formulation, but overestimated the ones of the adrenalinized lidocaine formulation.

The plot of its standardized residuals as a function of time was curvilinear (Fig 4A and 4C) and showed large variability in the first 50 minutes of sampling as compared to model B (Fig 4B and 4D), indicating that Model A did not predict the absorption and peak phases of the kinetic profiles of both lidocaine formulations. Therefore, model B was selected for further refinement.

Model C had the smallest AIC value (-2913.48) of all three models and, compared with Model B (Fig 5A and 5C), standardized residuals as a function of time were closer to the abscissa, in particular during the first 50 min following administration of either lidocaine formulation (Fig 5B and 5D).

The scattering of observed vs. model-predicted plasma concentration data of Model C was closer to the identity line and was less dependent on concentration as compared to Models A and B (Fig 6C vs. 6A and 6B).

Lidocaine absorption kinetics and adrenaline effects

Model C was selected to elucidate the absorption kinetics of lidocaine and examine the effect of adrenaline. Fig 7 presents the time-course of observed and model-predicted plasma lidocaine concentrations for two subjects, which respectively show the best (dog B) and worst (dog E) goodness-of-fit.

The estimated population pharmacokinetic parameters of lidocaine in dogs dosed with the plain and adrenalinized lidocaine formulations are detailed in Table 1. Adrenaline significantly decreased \( AUC_{0-t_{\text{last}}} \) by approximately 23%, \( C_{\text{max}} \) and \( \tau \) by 60%, \( k_{01} \) by 50% and \( k_{02} \) by 90% \((p < 0.05\) in all cases). It also significantly increased \( \text{Dur}_1 \) by 90%, and \( \text{Dur}_2 \) by and 1300% \((p < 0.02\), but did not significantly affect the estimated \( t_{\text{max}} \) and \( f \) of the tested formulations \((p > 0.05)\).

Discussion

The results reported herein support our hypothesis regarding the ability of our alternative compartmental model at accurately measuring the lowering effect of adrenaline on the
Fig 2. Individual time-courses of plasma lidocaine concentrations in dogs. (A) Paravertebral dosing of 6 mg/kg plain lidocaine formulation. (B) Paravertebral dosing of 6 mg/kg adrenalinated lidocaine formulation. The time-concentration data is delineated in linear coordinates (main graphs) and semilogarithmic coordinates (insert graphs).

doi:10.1371/journal.pone.0169745.g002
absorption rate of perineurally-administered lidocaine in dogs. The estimated absorption kinetic parameters reported in Table 1 are consistent with a slower, prolonged systemic uptake of the adrenalinated local anesthetic from the injection sites.

The absorption phase of lidocaine was visibly biphasic for both dosing formulations, with a first fraction \( f \) that was absorbed at a faster rate, and a second dose fraction \( (1 - f) \) that was absorbed at a slower rate. In the case of plain lidocaine, both absorption rates were faster than the elimination rate of lidocaine, which induced a shoulder in the absorption phase of the kinetic profile. But in the case of adrenalinated lidocaine, the 2\(^{nd} \) absorption rate was slower than the elimination rate of the drug (i.e. flip-flop kinetics), which induced either a plateau or a shallow decreasing slope after \( C_{\text{max}} \). This and the visible trends in the standardized regression residuals (Fig 3A and 3C and Fig 4A and 4C) warranted the rejection of the “null hypothesis” Model A despite its lower AIC value as compared to model B. Other investigators already have reported such biphasic absorption kinetics for lidocaine and other local anaesthetics in human beings [22–26]. The mechanistic basis of this model cannot be ascertained from our data, but at least 4 options are possible. First, the fast absorption compartment may represent the
dissolved drug molecules present at the site of injection receiving the highest blood supply, and the slow absorption compartment the drug molecules in a region of the injection site that receives a lower level of blood perfusion [25]. Second and consistent with our observations of dyes injected in the paravertebral brachial plexus of canine cadavers, the fast absorption compartment may represent an anatomical site proximal to a diffusion obstacle (i.e. fascia or fatty tissue), and the slow absorption compartment may represent the site distal to it. Third, the fast and slow absorption components may respectively reflect the blood vs. lymphatic transit pathways from the injection site to the systemic bloodstream. This possibility is receiving increased attention in parallel with the current development of therapeutic proteins and other large drug molecules [27]. Fourth, the dual fast/slow absorption may reflect a process of precipitation of this lipophilic drug at the site of injection. This phenomenon may result from the resorption of the aqueous drug solvent and the pH shift caused by the buffered interstitial fluids, which may increase the injection site drug concentration to the point of saturation [28].

Fig 4. Lidocaine standardized residuals of the standard and alternative compartmental models vs. time following lidocaine administration. (A) Plain lidocaine data predicted by Model A (i.e. one first-order absorption rate per system). (B) Plain lidocaine data predicted by Model B (i.e. two asynchronous first-order absorption rates per system). (C) Adrenalinated lidocaine data predicted by Model A. (D) Adrenalinated lidocaine data predicted by Model B. A third degree polynomial curve (continuous line) has been added to highlight the trend in the residuals.

doi:10.1371/journal.pone.0169745.g004
The regression residuals of model B (i.e. with asynchronous fast and slow first-order absorption rate constants) scattered randomly over the abscissa of model-predicted concentration (Fig 3B and 3D), but an N-shaped trend was detected for the residuals of the first 50 minutes after drug injection, especially with plain lidocaine administration (Fig 4B and 4D). Therefore, this model misspecification suggestive of an atypical drug absorption process warranted the refinement of model B [29].

One possible modification is to replace the dual first-order, asynchronous absorption rates with two zero-order, time-constrained absorption rates, a strategy tried for the PK modeling of the epidural block with levobupivacaine [15]. Although these investigators found that the goodness-of-fit of this alternative model was lower than their original model, other authors have found it useful to fit the i.m. absorption kinetics of several other aqueous drug products.
such as trovafloxacin [30], pralidoxime [31], or recombinant human luteinizing hormone [32]. Another possible modification is to use two asynchronous inverse-gaussian absorption processes, a strategy that successfully quantified the effect of adrenaline on the uptake of ropivacaine in a thoracic paravertebral or a femoral nerve block [25,26]. In the current study, we improved our model by using the dual zero-order, time-constrained, asynchronous absorption rates. This alternative Model C had a markedly lower AIC value as compared to models A and B, an improved overall goodness-of-fit (Fig 6C vs. 6A and 6B), and random scattering of residuals over the abscissas, both as a function of model-predicted lidocaine concentration and as a function of time (Figs 4B and 4D and 5B and 5D).

In contrast with the studies cited above [15,25,26], the time-course of plasma lidocaine concentration had quasi-straight absorption phase slopes with abrupt slope changes (Fig 7), a shape that resembles a short stepwise i.v. infusion and is suggestive of at least two zero-order absorption processes [29]. This hypothesis was confirmed by comparing the AIC for models B and C. Our study design cannot elucidate the physiological determinants of a zero-order absorption profile of the tested aqueous solutions of lidocaine hydrochloride, but such atypical absorption behavior may be associated with the lymphatic uptake of precipitated drug molecules [27], or their dissolution by the rate-limiting turnover of interstitial fluid, resulting in pseudo zero-order absorption [30]. Further research is needed to confirm this hypothesized mechanism for lidocaine hydrochloride [33].

In contrast with levobupivacaine [15] and ropivacaine in humans [25], the zero-order absorption rates ($k_{01}$ and $k_{02}$) of lidocaine, their respective durations (Dur$_1$ and Dur$_2$), and the lag time for the onset of the second absorption rate significantly differed between formulations ($P < 0.05$). These changes in the absorption kinetics of lidocaine resulted in a significantly lower $C_{\text{max}}$, hence a lower toxicity potential [34]. Interestingly, no significant difference was found for the partition coefficient $f$, a result that differs from the reported effect of adrenaline on the caudal epidural absorption kinetics of levobupivacaine in humans [15], and of ropivacaine injected paravertebrally in the thorax region [25]. In both studies, adrenaline significantly decreased the dose fraction that was absorbed from the fast-absorption compartment.

One limitation to our study is the lack of a study arm where each lidocaine solution was administered intravenously to the dogs. This precluded the estimation of the disposition...
pharmacokinetic parameters CL and V of its terminal elimination rate, and of the absolute bioavailability F. But using one or more i.v. study arms in the same dogs may decrease the intrinsic clearance of lidocaine [35], and therefore hinder the elucidation of the effects of adrenaline on its absorption kinetics. Still, the disposition pharmacokinetic parameters estimated in this study are comparable to those of previous studies: one reported a CL of 0.04 L·min⁻¹·kg⁻¹ and a V of 1.44 L·kg⁻¹ after a lidocaine i.v. bolus [18], and another reported a 70 min terminal half-life after a single intraperitoneal and incisional administration of lidocaine in dogs, with a calculated average CL/F of 0.056 L·min⁻¹·kg⁻¹ [36].

Additional limitations of this study include the small number of subjects, and the narrow blood-sampling window, especially for the adrenaline lidocaine administration. But the latter problem was circumvented by assuming that, at the dose and dosing interval used here, adrenaline has negligible effects on the disposition kinetics of lidocaine. This enables the use of a compartmental model where the PK systems for plain and adrenaline lidocaine share identical CL/F and V/F, and therefore the terminal slope can be detected even if

![Fig 7. Best and worst fits to the individual time-courses of plasma lidocaine concentration in dogs. Predicted plasma lidocaine concentrations were generated by the refined alternative model (i.e. Model C, with two time-constrained, asynchronous zero-order drug absorption rates per system). (A) Best fit: Dog B, plain lidocaine data. (B) Worst fit: Dog E, plain lidocaine data. (C) Best fit: Dog B, adrenaline lidocaine data. (D) Worst fit: Dog E, adrenaline lidocaine data. Cp, plasma drug concentration.

doi:10.1371/journal.pone.0169745.g007](https://doi.org/10.1371/journal.pone.0169745.g007)
one sampling time of the adrenalinated lidocaine formulation occurred in the elimination phase.

The tested drugs were administered under isoflurane general anesthesia, which was shown to alter lidocaine’s pharmacokinetic parameters in cats [11]. However, anesthesia was stopped as soon as the last block injection was completed, and therefore most blood samples were taken on ambulatory dogs.

Finally, with respect to the dosing schedule, differences in the early post-C\textsubscript{max} portion of the time-course of plasma lidocaine concentrations after dosing adrenalinated lidocaine on single vs. multiple paravertebral injection sites have been reported [37]. In our study, three injections were administered to each subject within a maximum window of four minutes, and the recorded slope of plasma drug concentrations did not change following each block injection. We therefore chose to consider our dosage regimen as a single administration.

### Conclusions

This crossover comparison of the pharmacokinetics of plain and adrenalinated lidocaine solutions in dogs subjected to a paravertebral brachial plexus block quantified the slowing effect of adrenaline on the systemic absorption rate of lidocaine. But most importantly, it revealed a previously unreported atypical absorption pattern for this local anaesthetic drug, which is independent of the presence of adrenaline. The physiological and/or physicochemical determinants of this sequential, time-constrained, zero-order absorption kinetics remain to be elucidated, but may explain our limited ability to predict the depth and duration of local anesthesia when the local anaesthetic is administered at different doses or in repeated dosings.

### Table 1. Estimated pharmacokinetic parameters of paravertebrally injected lidocaine in dogs, and statistical comparison of plain and adrenalinated formulations.

| Parameter | Unit             | Source | Plain formulation | Both formulations | Adrenalinated formulation | \( P \) value |
|-----------|------------------|--------|-------------------|-------------------|--------------------------|-------------|
| CL/F      | L min\(^{-1}\) kg\(^{-1}\) | Model  | 0.017 (0.005)     | 0.850 (0.580)     | -                        | -           |
| V/F       | L kg\(^{-1}\)    | Model  | 0.009 (0.004)     | 75.0 (32.3)       | -                        | -           |
| AUC\(_{0-t_{\text{last}}}\) | min-mg L\(^{-1}\) | Data   | 281.8 (83.2)      | 215.9 (69.1)      | 0.0321                   |
| C\(_{\text{max}}\) | mg L\(^{-1}\)   | Data   | 2.944 (0.818)     | 1.847 (0.636)     | < 0.0001                 |
| t\(_{\text{max}}\) | min             | Data   | 19.72 (9.99)      | 13.53 (7.74)      | 0.1556                   |
| Dur\(_{1}\) | min             | Model  | 5.77 (3.24)       | 11.30 (7.05)      | 0.0197                   |
| Dur\(_{2}\) | min             | Model  | 18.10 (4.87)      | 254.00 (129.00)   | < 0.0001                 |
| \( k_{\text{f1}} \) | mg min\(^{-1}\) | Model  | 0.075 (0.055)     | 0.037 (0.029)     | 0.0463                   |
| \( k_{\text{f2}} \) | mg min\(^{-1}\) | Model  | 0.013 (0.008)     | 0.001 (0.001)     | < 0.0001                 |
| f         | mg mg\(^{-1}\)  | Model  | 0.56 (0.22)       | 0.54 (0.15)       | 0.3640                   

Estimated pharmacokinetic parameters are expressed as log-normal means (log-normal SD), and were derived directly from the time-concentration data, or as the result of analysis with the refined alternative pharmacokinetic model (i.e. Model C, with two time-constrained, asynchronous zero-order absorption rates per system). AUC\(_{0-t_{\text{last}}}\), area under the plasma concentration curve between the time of dosing and the time of last measurable plasma concentration; CL/F, apparent total plasma clearance; C\(_{\text{max}}\), maximum plasma concentration; Dur\(_{1}\), duration of the early absorption phase; Dur\(_{2}\), duration of the late absorption phase; f, Dose fraction absorbed during the early absorption phase; \( k_{\text{f1}} \), zero-order rate of the early absorption phase; \( k_{\text{f2}} \), zero-order rate of the late absorption phase; \( \lambda_{z} \), terminal disposition rate constant; t\(_{1/2}\), terminal half-life; \( \tau \), delay to the onset of the late absorption phase; t\(_{\text{max}}\), time of maximum plasma concentration; V/F, apparent distribution volume.

doi:10.1371/journal.pone.0169745.t001
Supporting Information

S1 File. Lidocaine time-concentration data in dogs dosed paravertebrally with plain and adrenalinated lidocaine formulations. Subject#, subject number; ID, identification; Formulation, lidocaine formulation used; Time (min), time following the initiation of the 1st injection; Cp (mg/L), plasma lidocaine concentration (mg/L).

Acknowledgments

We are grateful to Mrs. Myriam Charest, D.M.V. student, Mrs. Dominique Gauvin, M.Sc., and Mrs. Johanne Couture, D.E.C. for their valuable assistance in data collection and blood sample analysis, as well as to FUJIFILM Sonosite Inc., Markham (On), Canada, for generously lending the ultrasound equipment.

Author Contributions

Conceptualization: AC, ET, JREdC.
Data curation: JREdC.
Formal analysis: JREdC, AC.
Funding acquisition: ET, AC.
Investigation: AC, MG.
Methodology: AT, EC, JREdC.
Project administration: AC, ET.
Resources: ET, FV.
Software: JREdC.
Supervision: ET, JREdC, FV.
Validation: AC, ET, JREdC.
Visualization: JREdC.
Writing – original draft: AC, JREdC, ET, FV.
Writing – review & editing: AC, JREdC.

References

1. Skarda TR, Tranquilli WJ. Local and regional anesthetic and analgesic techniques: dogs. In: Tranquilli WJ, Thurmon JC, Grimm KA, editors. Lumb and Jones' Veterinary Anesthesia and Analgesia, 4th ed. Ames: Blackwell Publishing; 2007. pp 561–93.
2. O'Donnell BD, Iohom G. An estimation of the minimum effective anesthetic volume of 2% lidocaine in ultrasound-guided axillary brachial plexus block. Anesthesiology. 2009; 111: 25–29. doi: 10.1097/ALN.0b013e3181a915c7 PMID: 19512869
3. Mosing M, Reich H, Moens Y. Clinical evaluation of the anaesthetic sparing effect of brachial plexus block in cats. Vet Anaesth Analg. 2010; 37: 154–161. doi: 10.1111/j.1467-2995.2009.00509.x PMID: 20230566
4. Trumpatori BJ, Carter JE, Hash J, Davidson GS, Matthews KG, Roe SC, et al. Evaluation of midhumeral block of the radial, ulnar, musculocutaneous and median (RUMM block) nerves for analgesia of the distal aspect of the thoracic limb in dogs. Vet Surg. 2010; 39: 785–796. doi: 10.1111/j.1532-950X.2010.00712.x PMID: 20873276
5. Bailey CS, Kitchell RL. Cutaneous sensory testing on the dog. J Vet Intern Med. 1987; 1: 128–135. PMID: 333411

6. Duke T. Local and regional anesthetic and analgesic techniques in the dog and cat: Part 2, infiltration and nerve blocks. Can Vet J. 2000; 41: 949–952. PMID: 11143931

7. Lermke KA, Creighton C. Paravertebral blockade of the brachial plexus in dogs. Vet Clin North Am Small Anim Pract. 2008; 38: 1231–1241. doi: 10.1016/j.cvsm.2008.06.003 PMID: 18954682

8. Bennet PN, Aarons LJ, Bending MR, Steiner JA, Rowland M. Pharmacokinetics of lidocaine and its deethylated metabolite: dose and time dependency studies in man. J Pharmacokinet Biopharm. 1982; 10: 265–281. PMID: 7175699

9. Cox S, Wilson J, Doherty T. Pharmacokinetics of lidocaine after intravenous administration to cows. J Vet Pharmacol Ther. 2012; 35: 305–308. doi: 10.1111/j.1365-2885.2011.01328.x PMID: 21831114

10. Feary DJ, Mama KR, Wagner AE, Thomasy S. Influence of general anesthesia on pharmacokinetics of intravenous lidocaine infusion in horses. Am J Vet Res. 2005; 66: 574–580. PMID: 15900935

11. Thomasy SM, Pypendop BH, Ilkiv JE, Stanley SD. Pharmacokinetics of lidocaine and its active metabolite, monoethylglycinexylidide, after intravenous administration of lidocaine to awake and isoflurane-anesthetized cats. Am J Vet Res. 2005; 66: 1162–1266. PMID: 16111153

12. Gerner P, Wang CF, Lee BS, Suzuki S, Degirolami U, Gandhi A, et al. The relationship between functional sciatic nerve block duration and the rate of release of lidocaine from a controlled-release matrix. Anesth Analg. 2010; 111: 221–229. PMID: 20522702

13. Skarda TR, Tranquilli WJ. Local anesthetics. In: Tranquilli WJ, Thurmon JC, Grimm KA, editors. Lumb and Jones' Veterinary Anesthesia and Analgesia, 4th ed. Ames: Blackwell Publishing, 2007. pp 395–418.

14. Sinnott CJ, Cogswell LP, Johnson A, Strichartz GR. On the mechanism by which epinephrine potentiates lidocaine’s peripheral nerve block. Anesthesiology. 2003; 98: 181–188. PMID: 12502995

15. Chalkiadis GA, Abdullah F, Bjorksten AR, Clarke A, Cortinez LI, Udayasiri S, et al. Absorption characteristics of epidural levobupivacaine with adrenaline and clonidine in children. Paediatr Anaesth. 2013; 23: 58–67. doi: 10.1111/pan.12074 PMID: 23167288

16. Bagshaw HS, Larenza MP, Seiler GS. A technique for ultrasound-guided paravertebral brachial plexus injections in dogs. Vet Radiol Ultrasound. 2009; 50: 649–654. PMID: 19999352

17. Choquette A, del Castillo JRE, Moreau M, Guilhot M, Alexander K, Kona-Boun JJ, et al. Comparison of lidocaine and lidocaine-adrenaline for the paravertebral brachial plexus block in dogs. Vet Anesth Analg. 2016 (manuscript number VAA-15-0090 in press).

18. Wilcke JR, Davis LE, Neff-Davis CA, Koritz GD. Pharmacokinetics of lidocaine and its active metabolites in dogs. J Vet Pharmacol Ther. 1983; 6: 49–52. PMID: 6854732

19. Gaudreauit F, Drolet P, Varin F. High-performance liquid chromatography using UV detection for the simultaneous quantification of ropivacaine and bupivacaine in human plasma. Ther Drug Monit. 2009; 31: 753–757. PMID: 19809388

20. D’Argenio DZ, Schumitzky A, Wang X. ADAPT 5 User’s Guide: Pharmacokinetic/Pharmacodynamic Systems Analysis Software. Los Angeles: Biomedical Simulations Resource, 2009.

21. Yamaoka K, Nakagawa T, Uno T. Application of Akaike’s Information Criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokin Biopharm. 1978; 6: 165–175. PMID: 671222

22. Burm AG, Vermeulen NP, van Kleef JW, de Boer AG, Spierdijk J, Breimer DD. Pharmacokinetics of lidocaine and bupivacaine in surgical patients following epidural administration simultaneous investigation of absorption and disposition kinetics using stable isotopes. Clin Pharmacokinet. 1987; 13: 191–203. PMID: 3665324

23. Tucker GT, Mather LE. Clinical pharmacokinetics of local anaesthetics. Clin Pharmacokinet. 1979; 4: 241–278. PMID: 385208

24. Simon MJ, Veering BT, Stienstra R, van Kleef JW, Burm AG. Effect of age on the clinical profile and systemic absorption and disposition of levobupivacaine after epidural administration. Br J Anaesth. 2004; 93: 512–520. doi: 10.1093/bja/aeh241 PMID: 15321929

25. Karmarkar MK, Ho AM, Law BK, Wong AS, Shafer SL, Gin T. Arterial and venous pharmacokinetics of ropivacaine with and without epinephrine after thoracic paravertebral block. Anesthesiology. 2005; 103: 704–711. PMID: 16192762

26. Gaudreauit F, Drolet P, Fallaha M, Varin F. A population pharmacokinetic model for the complex systemic absorption of ropivacaine after femoral nerve block in patients undergoing knee surgery. J Pharmacokinet Pharmacodyn. 2012; 39: 635–642. doi: 10.1007/s10928-012-9275-z PMID: 23054251

27. McLennan DN, Porter CJ, Charman SA. Subcutaneous drug delivery and the role of the lymphatics. Drug Discov Today Technol. 2005; 2: 89–96. doi: 10.1016/j.ddtec.2005.05.006 PMID: 24981760
28. Ballard BE. Lidocaine hydrochloride absorption from a subcutaneous site. J Pharm Sci. 1975; 64: 781–784. PMID: 239197

29. Zhou H. Pharmacokinetic strategies in deciphering atypical drug absorption profiles. J Clin Pharmacol. 2003; 43: 211–227. PMID: 12638389

30. Mahmood AH, Liu X, Grice JE; Medley GA, Roberts MS. Using deconvolution to understand the mechanism for variable plasma concentration—time profiles after intramuscular injection. Int J Pharm. 2015; 481: 71–78. doi: 10.1016/j.ijpharm.2015.01.046 PMID: 25636300

31. Abbara C, Rousseau JM, Lelièvre B, Tuncart A, Lallement G, Ferec S, et al. Pharmacokinetic analysis of pralidoxime after its intramuscular injection alone or in combination with atropine-avizafone in healthy volunteers. Br J Pharmacol. 2010; 161: 1857–1867. doi: 10.1111/j.1476-5381.2010.01007.x PMID: 20804498

32. le Cotonnec JY, Porchet HC, Bietrami V, Munafò A. Clinical pharmacology of recombinant luteinizing hormone: Part II. Bioavailability of recombinant human luteinizing hormone assessed with an immunoassay and an in vitro assay. Fertil Steril. 1998; 69: 195–200.

33. Wu Z, Hassan D, Shaw JP. In-vitro prediction of bioavailability following extravascular injection of poorly soluble drugs: an insight into clinical failure and the role of delivery systems. J Pharm Pharmacol. 2013; 65: 1429–1439. doi: 10.1111/jphp.12114 PMID: 24028610

34. Burm AG, van Kleef JW, Gladines MP, Olthof G, Spierdijk J. Epidural anesthesia with lidocaine and bupivacaine: effects of epinephrine on the plasma concentration profile. Anesth Analg. 1986; 65: 1281–1284. PMID: 3777457

35. Ngo LY, Tam YK, Tawfik S, Coutts RT, Gray MR. Effects of intravenous infusion of lidocaine on its pharmacokinetics in conscious instrumented dogs. J Pharm Sci. 1997; 86: 944–952. doi: 10.1021/js960399i PMID: 9269873

36. Wilson DV, Barnes KS, Hauptman JG. Pharmacokinetics of combined intraperitoneal and incisional lidocaine in the dog following ovariohysterectomy. J Vet Pharmacol Ther. 2004; 27: 105–109. doi: 10.1111/j.1365-2885.2004.00552.x PMID: 15096108

37. Lemay E, Guay J, Côté C, Boivin MC, Varin F. The number of injections does not influence local anesthetic absorption after paravertebral blockade. Can J Anaesth. 2003; 50: 562–527. doi: 10.1007/BF03018641 PMID: 12826547